My ePortfolio Register   

De-escalating and escalating surgery in the management of early breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.03.17
Views: 1218
Rating:

Dr Monica Morrow - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Morrow speaks with ecancer at 2017 St. Gallen International Breast Cancer Conference about how to control the intensity and side effects of treating breast cancer. 

She notes the potential implications of de-escalating surgery for ductal carcinoma in situ (DCIS), and gives long-term results for early stage breast cancer patients who can avoid axillary dissection with low risk of local recurrence.

Finally, Dr Morrow describes prospective studies showing that negative sentinel node biopsy indicates no benefit from axillary dissection, and weighs how tumour genotyping can guide treatment choices and timing between surgical of chemotherapeutic intervention.

Her work is also discussed by Dr Philip Poortmans here.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence